Table 2.
Cause-specific HRs for new-onset cardiovascular disease among patients with DLBCL from unadjusted and adjusted analyses including with and without 9-mo landmark period (N = 2600) in Hong Kong, 2000-2018
| Characteristic* | No landmark period | 9-mo landmark period | ||||||
|---|---|---|---|---|---|---|---|---|
| Unadjusted HR (95% CI)† | P | Adjusted HR (95% CI)† | P | Unadjusted HR (95% CI)† | P | Adjusted HR (95% CI)† | P | |
| Treatment factors | ||||||||
| Chemotherapy | ||||||||
| Doxorubicin ≤500 mg vs non-doxorubicin regimen | 0.86 (0.61-1.22) | .405 | 0.98 (0.66-1.44) | .902 | 0.89 (0.59-1.36) | .599 | 1.21 (0.75-1.94) | .437 |
| Doxorubicin >500 mg vs non-doxorubicin regimen | 1.03 (0.58-1.82) | .927 | 1.43 (0.76-2.71) | .270 | 1.16 (0.60-2.25) | .651 | 2.55 (1.18-5.53) | .017 |
| Receipt of RT | 1.24 (0.80-1.90) | .333 | 0.81 (0.47-1.41) | .464 | 1.07 (0.61-1.87) | .805 | 0.59 (0.30-1.15) | .120 |
| Rituximab | 0.82 (0.58-1.14) | .244 | 0.60 (0.39-0.93) | .023 | 0.81 (0.54-1.21) | .302 | 0.68 (0.41-1.15) | .154 |
| Patient factors | ||||||||
| Age at lymphoma diagnosis (per 1-y increase) | 1.05 (1.04-1.06) | <.001 | 1.01 (1.00-1.03) | .138 | 1.05 (1.04-1.06) | <.001 | 1.01 (0.99-1.03) | .409 |
| Sex (male vs female) | 1.15 (0.85-1.56) | .350 | 1.08 (076-1.54) | .645 | 1.12 (0.78-1.61) | .536 | 1.01 (0.66-1.55) | .966 |
| RCS comorbidity score‡ | ||||||||
| 1 vs 0 | 2.49 (1.76-3.52) | <.001 | 1.16 (0.77-1.76) | .473 | 2.41 (1.57-3.70) | <.001 | 1.11 (0.67-1.83) | .687 |
| 2 vs 0 | 5.24 (3.59-7.66) | <.001 | 1.01 (0.59-1.72) | .967 | 5.86 (3.75-9.17) | <.001 | 0.99 (0.53-1.94) | .974 |
| Year of diagnosis | ||||||||
| 2005-2009 vs 2000-2004 | 1.16 (0.77-1.75) | .471 | 1.16 (0.72-1.89) | .540 | 1.02 (0.64-1.62) | .921 | 1.03 (0.60-1.76) | .917 |
| 2010-2014 vs 2000-2004 | 0.83 (0.53-1.28) | .396 | 0.92 (0.52-1.64) | .776 | 0.76 (0.45-1.26) | .281 | 0.76 (0.40-1.44) | .400 |
| 2015-2018 vs 2000-2004 | 0.70 (0.39-1.24) | .221 | 1.08 (0.54-2.16) | .823 | 0.20 (0.06-0.67) | .009 | 0.28 (0.07-1.10) | .068 |
| Fee waiver recipients (surrogate for lower socioeconomic status) | 1.74 (1.11-2.72) | .015 | 1.12 (0.66-1.90) | .661 | 1.84 (1.09-3.13) | .023 | 1.14 (0.62-2.11) | .675 |
| COPD or smoker | 1.94 (1.43-2.63) | <.001 | 1.27 (0.89-1.81) | .192 | 2.12 (1.48-3.05) | <.001 | 1.32 (0.86-2.02) | .203 |
| Diabetes mellitus | 2.65 (1.96-3.59) | <.001 | 1.16 (0.79-1.72) | .442 | 2.36 (1.62-3.43) | <.001 | 0.85 (0.53-1.36) | .495 |
| Hypertension | 46.70 (11.58-188.25) | <.001 | 6.62 (1.45-30.10) | .014 | 68.14 (9.52-487.82) | <.001 | 6.21 (0.80-48.43) | .081 |
| Dyslipidemia/hyperlipidemia | 2.86 (2.12-3.86) | <.001 | 1.01 (0.71-1.44) | .953 | 3.28 (2.29-4.71) | <.001 | 1.18 (0.77-1.82) | .444 |
| Anxiety or depressive disorders | 1.38 (0.96-1.98) | .085 | 0.98 (0.66-1.47) | .941 | 1.36 (0.88-2.12) | .167 | 0.90 (0.56-1.43) | .650 |
| ACE inhibitor use | 5.24 (3.87-7.09) | <.001 | 1.95 (1.30-2.93) | .001 | 5.52 (3.82-7.97) | <.001 | 2.13 (1.32-3.42) | .002 |
| Beta blocker use | 5.14 (3.74-7.07) | <.001 | 1.66 (1.12-2.44) | .011 | 7.07 (4.69-10.65) | <.001 | 2.18 (1.32-3.60) | .002 |
| Aspirin use | 9.71 (6.90-13.67) | <.001 | 4.35 (2.80-6.76) | <.001 | 11.60 (7.51-17.93) | <.001 | 4.63 (2.54-8.43) | <.001 |
*
Race, alcohol-related diseases, and atrial fibrillation were not adjusted in the model because most of the patients were Hong Kong Chinese and too few patients had alcohol-related diseases and atrial fibrillation.
†
Cause-specific HRs by competing risk analyses.
‡
Included peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, liver disease, hemiplegia/paraplegia, renal disease, AIDS/HIV infection.